Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split-face comparison of microneedling alone versus microneedling combined with botulinum toxin A, autologous stem cells, or irradiated amniotic collagen for atrophic acne scars
PACTR202508850407266Phase 0Completed
- Sponsor
- Tanta University
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 0, open-label trial of botulinum toxin type A and Autologous Mesenchymal Stem Cells in atrophic acne scar, sponsored by Tanta University. Primary endpoint: Efficacy and safety evaluation. Started Jan 2024; status: completed.
02
Drugs
botulinum toxin type AAutologous Mesenchymal Stem Cells
03
Conditions
atrophic acne scar
Beyond the preview
Go deeper on PACTR202508850407266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202508850407266.